SBRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sabra Health Care REIT Inc (SBRA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has some positive aspects, such as bullish moving averages and a SwingMax signal from February 2026, the lack of significant upward momentum, declining financial performance, and neutral sentiment from hedge funds and insiders suggest a cautious approach. The investor may consider holding off on buying until there is a clearer positive catalyst or improvement in financial performance.
The stock's technical indicators are mixed. While the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is negative and expanding downward, and the RSI is neutral at 43.638. The stock is trading near its support level (S1: 19.998) but below the pivot point (20.456), indicating limited upward momentum.
SwingMax signal from February 2026 with a 4.52% price increase since then.
Analysts have raised price targets, with Citi and BofA analysts maintaining Buy ratings and targets of $24 and $23, respectively.
Revenue increased by 16.21% YoY in Q4 2025.
Net income dropped by 41.70% YoY, and EPS fell by 42.11% YoY in Q4
Gross margin declined by 8.17% YoY.
No significant hedge fund or insider trading activity, indicating neutral sentiment.
MACD is negative, and RSI is neutral, showing no strong upward momentum.
In Q4 2025, Sabra Health Care's revenue grew by 16.21% YoY to $211.9M. However, net income dropped by 41.70% YoY to $27.2M, and EPS fell by 42.11% YoY to $0.11. Gross margin also declined by 8.17% YoY to 63.75%.
Analysts have raised price targets, with Citi and BofA analysts maintaining Buy ratings and targets of $24 and $23, respectively. However, other analysts, such as UBS, Cantor Fitzgerald, and Truist, maintain Neutral or Hold ratings, reflecting mixed sentiment on the stock's near-term prospects.
